Drug Action
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Source page 755
Loading InternPractice…
Individual generic drug information
Extracted information for Sitagliptin only.
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Source page 755
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic control ▶BY MOUTH ▶Adult: 100 mg once daily, for further information on use with other antidiabetic drugs—consult product literature
Source page 755
DUE TO INTERACTIONS ▶Dose of concomitant sulfonylurea or insulin may need to be reduced.
Source page 755
Ketoacidosis
Source page 755
Scottish Medicines Consortium (SMC) decisions SMC No. 607/10 The Scottish Medicines Consortium has advised (July 2010) that sitagliptin (Januvia ®) is accepted for restricted use within NHS Scotland as monotherapy, to improve glycaemic control in patients with type 2 diabetes mellitus, for whom both metformin and sulfonylureas are not appropriate. SMC No. 1083/15 The Scottish Medicines Consortium has advised (September 2015) that sitagliptin (Januvia ®) is accepted for use within NHS Scotland as an add-on to insulin (with or without metformin) to improve glycaemic control in adults with type 2 diabetes mellitus.
Source page 756
Extracted information for Sitagliptin only.
→Appendix 1: sitagliptin
Source page 755
▶Common or very common Headache ▶Uncommon Constipation. dizziness. skin reactions ▶Frequency not known Angioedema. back pain. cutaneous vasculitis. interstitial lung disease. joint disorders. myalgia. pancreatitis acute. renal impairment. Stevens- Johnson syndrome. vomiting SIDE-EFFECTS, FURTHER INFORMATION Discontinue if symptoms of acute pancreatitis occur such as persistent, severe abdominal pain. Endocrine system
Source page 756
Avoid—toxicity in animal studies.
Source page 756
Avoid—present in milk in animal studies.
Source page 756
Dose adjustments Manufacturer advises reduce dose to 50 mg once daily if eGFR 30–45 mL/minute/1.73 m2. Manufacturer advises reduce dose to 25 mg once daily if eGFR less than 30 mL/minute/1.73 m2.
Source page 756
Extracted information for Sitagliptin only.
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Januvia (Merck Sharp & Dohme Ltd) Sitagliptin (as Sitagliptin phosphate) 25 mg Januvia 25mg tablets | 28 tablet P £33.26 DT = £33.26 Sitagliptin (as Sitagliptin phosphate) 50 mg Januvia 50mg tablets | 28 tablet P £33.26 DT = £33.26 Sitagliptin (as Sitagliptin phosphate) 100 mg Januvia 100mg tablets | 28 tablet P £33.26 DT = £33.26
Source page 756
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
100 mg once daily, for further information on
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 755